Akari Therapeutics Adds RNA Biology Expert to Scientific Advisory Board
Event summary
- Akari Therapeutics appointed Olga Anczukow, Ph.D., a globally recognized expert in RNA biology and cancer research, to its Scientific Advisory Board on February 23, 2026.
- Dr. Anczukow is an Associate Professor at The Jackson Laboratory for Genomic Medicine and a Co-Program Leader at the NCI-designated Jackson Laboratory Cancer Center.
- Akari Therapeutics is developing antibody drug conjugates (ADCs) with a novel PH1 payload targeting RNA splicing in cancer cells.
- The company's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and is designed to deliver the PH1 payload directly into the tumor.
- Akari Therapeutics plans to initiate IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027.
The big picture
Akari Therapeutics' appointment of Dr. Olga Anczukow to its Scientific Advisory Board underscores the company's focus on leveraging cutting-edge RNA biology research to advance its oncology pipeline. This strategic move aligns with the broader industry trend of targeting RNA splicing mechanisms in cancer treatment, which has shown promise in preclinical studies. The addition of Dr. Anczukow's expertise could accelerate the development of Akari's novel PH1 payload and its lead candidate, AKTX-101, as the company prepares for clinical trials.
What we're watching
- Scientific Advisory Board Impact
- How Dr. Anczukow's expertise in RNA splicing and cancer biology will shape Akari Therapeutics' research strategy and evaluate emerging scientific opportunities.
- Clinical Development Timeline
- The pace at which Akari Therapeutics advances AKTX-101 through IND enabling studies and initiates its First-In-Human trial by late 2026/early 2027.
- Therapeutic Synergy
- Whether the PH1 payload's ability to disrupt RNA splicing in cancer cells will demonstrate synergistic potential with checkpoint inhibitors and other therapies.
Related topics